Importantly, LOC285194 serves as a carcinoma inhibitor by targeting p53 through KRAS/BRAF/SMEK pathway in nonsmall cell carcinoma of lung.15 In esophageal squamous cell carcinoma, LOC285194 also participates in chemoradiotherapy resistance.16 In our investigation, we determined that LOC285194 was notably downregulated within GC cells. This evidence concerns the gene KRAS and esophageal squamous cell carcinoma.